Calcium concentration in the CAPD dialysate: What is optimal and is there a need to individualize?

Peritoneal Dialysis International

Volumn 17, Issue 6, 1997, Pages 554-559

  Bro, Susanne ^a,b   Brandi, Lisbet ^a   Daugaard, Henrik ^a   Olgaard, Klaus ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Hypercalcemia; Hypocalcemia; PTH suppression; Reduced dialysate calcium; Secondary hyperparathyroidism

Indexed keywords

ALUMINUM; CALCIUM; CALCIUM CARBONATE; PHOSPHATE BINDING AGENT; VITAMIN D DERIVATIVE;

ARTICLE; CALCIUM BLOOD LEVEL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIALYSATE; DRUG TOLERANCE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; MAJOR CLINICAL STUDY; METABOLITE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RISK; SECONDARY HYPERPARATHYROIDISM;

EID: 0031406316     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089701700606     Document Type: Article

References (33)

1. Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Miner Electrolyte Metab 1995; 21:91-6.
2. Brancaccio D, Gallieni M, Cozzolino M. Treatment of hyperparathyroidism - why is it crucial to control serum phosphate? Nephrol Dial Transplant 1996; 11:420-3.
3. Delmez JA. The spectrum of renal osteodystrophy in peritoneal dialysis patients. Perit Dial Int 1996; 16:24-5.
4. Hutchison AJ, Gokal R. Reduced calcium dialysis fluids: What's the point? Perit Dial Int 1996; 16:252-4.
5. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992; 75:145-50.
6. Torres A, Lorenzo V, Hernandez D, Rodriguez JC, Concepcion MT, Rodriguez AP, et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better response to PTH. Kidney Int 1995; 47:1434-42.
7. Ritz E, Mehls O. Vitamin D therapy in patients receiving dialysis. Adv Ren Replace Ther 1995; 2(1):14-19.
8. Coburn JW. Mineral metabolism and renal bone disease: effects of CAPD versus hemodialysis. Kidney Int 1993; 43(Suppl 40):S92-100.
9. Armstrong A, Cunningham J. The treatment of metabolic bone disease in patients on peritoneal dialysis. Kidney Int 1994; 46(Suppl 48):S51-7.
10. Weinreich T, Ritz E, Passlick-Deetjen J for the Collaborators of the Peritoneal Dialysis Multicenter Study Group. Long-term dialysis with low-calcium solution (1.00 mmol/L) in CAPD: effects on bone mineral metabolism. Perit Dial Int 1996; 16(3):260-8.
11. Hamdy NAT, Boletis J, Charlesworth D, Kanis JA, Brown CB. Low calcium dialysate increases the tolerance to vitamin D in peritoneal dialysis. In: La Greca G, Olivares J, Feriani M, Passlick-Deetjen J, eds. CAPD - a decade of experience. Contrib Nephrol 1991; 89:190-8.
12. 3 and low-calcium dialysis (1.25 mmol/L) on secondary hyperparathyroidism in patients on CAPD. Submitted to J Int Med.
13. Buijsen CGM, Struijk DG, Huijgen HJ, Boeschoten EW, Wilmink JM. Can low-calcium peritoneal dialysis solution safely replace the standard calcium solution in the majority of chronic peritoneal dialysis patients? Perit Dial Int 1996; 16:497-504.
14. Bro S, Brandi L, Olgaard K. High-normal calcium (1.35 mmol/L) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate and parathyroid hormone. Nephrol Dial Transplant 1996; 11:1586-91.
15. Honkanen E, Kala AR, Grönhagen-Riska C, Ikäheimo R. CAPD with low calcium dialysate and calcium carbonate: results of a 24-week study. In: Khanna R, Nolph KD, Prowant BF, Twardowski ZJ, Oreopoulos DG, eds. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin, 1992; 8:356-61.
16. Johnson DW, Rigby RJ, McIntyre HD, Brown A, Freeman J. A randomized trial comparing 1.25 mmol/L calcium dialysate to 1.75 mmol/L calcium dialysate in CAPD patients. Nephrol Dial Transplant 1996; 11:88-93.
17. Hutchison AJ, Freemont AJ, Boulton HF, Gokal R. Low-calcium dialysis fluid and oral calcium carbonate in CAPD. A method of controlling hyperphosphataemia whilst minimizing aluminium exposure and hypercalcaemia. Nephrol Dial Transplant 1992; 7:1219-25.
18. Piraino B, Perlmutter JA, Holley JL, Johnston JR, Bernardini J. The use of dialysate containing 2.5 mEq/L calcium in peritoneal dialysis patients. Perit Dial Int 1992; 12:75-6.
19. Rotellar C, Kinsel V, Goggins M, Tarman G, Stull M, Mazzoni MJ, et al. Does low-calcium dialysate accelerate secondary hyperparathyroidism in continuous ambulatory peritoneal dialysis patients? Perit Dial Int 1993; 13(Suppl 2):S471-2.
20. Wadhwa NK, Howell N, Suh H, Cabralda T. Low calcium (2.5 mEq/L) and high calcium (3.5 mEq/L) dialysate in peritoneal dialysate patients. In: Khanna R, Nolph KD, Prowant BF, Twardowski ZJ, Oreopoulos DG, eds. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin, 1992; 8:385-8.
21. Weinreich T, Passlick-Deetjen J, Ritz E for the Collaborators of the Peritoneal Dialysis Multicenter Study Group. Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial. Am J Kidney Dis 1995; 25(3):452-60.
22. Bro S, Brandi L, Olgaard K. Risk/benefit in prophylaxis and treatment of secondary hyperparathyroidism. A comparison of two low calcium peritoneal dialysis fluids. Nephrol Dial Transplant 1996; 11(Suppl 3):47-9.
23. Duncan R, Cochrane T, Bhalla C, Michael J, Richards NT, Adu D. Low calcium dialysate and hyperparathyroidism. Perit Dial Int 1996; 16(Suppl 1):S499-502.
24. Cunningham J, Beer J, Coldwell RD, Noonan K, Sawyer N, Makin HLJ. Dialysate calcium reduction in CAPD patients treated with calcium carbonate and alfacalcidol. Nephrol Dial Transplant 1992; 7:63-8.
25. Beer J, Noonan K, Cunningham J. 0.6 mM calcium dialysate in CAPD: Effective strategy for treating persistent hypercalcemia in patients receiving CAPD (Abstract). Nephrol Dial Tranplant 1992; 7(7):753.
26. Scanziani R, Dozio B, Bonforte G, Surian M. Effects of calcitriol - pulse therapy per os in CAPD patients. In: Khanna R, ed. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Publications, 1994; 10:270-4.
27. 2+ peritoneal dialysis solution. Perit Dial Int 1992; 13(Suppl 2):473-5.
28. Cheng IKP, Lu HB, Chan CY, Cheng SW, Robinson JD, Tam SCF, et al. The requirement of low calcium dialysate in patients on continuous ambulatory peritoneal dialysis receiving calcium carbonate as a phosphate binder. Clin Nephrol 1993; 40(2):100-5.
29. Hercz G, Pei Y, Greenwood C, Manuel A, Saiphoo C, Goodman WG, et al. Aplastic osteodystrophy without aluminium: The role of "suppressed" parathyroid function. Kidney Int 1993; 44:860-6.
30. Hutchison AJ, Gokal R. Improved solutions for peritoneal dialysis: physiological calcium solutions, osmotic agents and buffers. Kidney Int 1992; 42(Suppl 38):153-9.
31. Kawanishi H, Tsuchiya T, Namba S, Takahashi N, Toyota T, Fukuma K, et al. Clinical application of low calcium peritoneal dialysate. ASAIO Trans 1991; 37:404-6.
32. Martis L, Zimmerman SW, Delmez JA, Nolph KD, Serkes KD, Algrim CE, et al. Dianeal 2.5 mEq/L calcium and calcium carbonate in CAPD (Abstract). Perit Dial Int 1992; 12(Suppl 1):S139.
33. Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D, et al. Poly(allylamine hydrochloride) (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997; 29(1):66-71.